[논문]다제내성결핵 환자에서 메타분석을 통한 Linezolid의 효능 및 안전성 평가

정우진; 성태욱; 김애진; 채정우; 윤휘열

doi:10.24304/kjcp.2023.33.4.278

[국내논문] 다제내성결핵 환자에서 메타분석을 통한 Linezolid의 효능 및 안전성 평가
Evaluation of the Efficacy and Safety of Linezolid by Meta-analysis for Multidrug-resistant Tuberculosis Patients 원문보기

한국임상약학회지 = Korean journal of clinical pharmacy, v.33 no.4, 2023년, pp.278 - 289

정우진 (충남대학교 약학대학) , 성태욱 (충남대학교 약학대학) , 김애진 (충남대학교 약학대학) , 채정우 (충남대학교 약학대학) , 윤휘열 (충남대학교 약학대학)

Abstract ▼ AI-Helper

Background: Linezolid has been widely used in the treatment for multidrug-resistant tuberculosis. However, there are limitations to use it such as long treatment, because of related side effects, even adequate treatment period has been needed for remission of multidrug-resistant tuberculosis (MDR-TB). Method: The meta-analysis was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. To choose literatures, systematic literature reviews were conducted with databases of PubMed, Web of Science, and EMBASE. Results: Efficacy and safety of Linezolid were determined by 85% (95% CI=79~89%, p<0.05) in the sputum culture conversion and 55% (95% CI=45~64%, p<0.01) in side effects related to linezolid, respectively. In addition, I2 was estimated by 72%. In the subgroup analysis, efficacy and safety by dose and region were analyzed. In the subgroup analysis, compared with the linezolid dose in groups greater than 600 mg/day and less than 600 mg/day, this study showed 85% (95% CI 79~90%, p>0.05) in 206 patients and 82% (95% CI 73~89%, p<0.05) in 297 patients, respectively. Also, in the subgroup analysis, adverse effects caused by linezolid occurred more than 50% of treated patients. Conclusion: Therapeutic efficacy of linezolid for MDR-TB patients was confirmed regardless of the initial dose of linezolid, especially for sputum culture conversion and it was recommended that the dose of linezolid has been more effective below 600 mg/day. However, it should be necessary to closely monitored for safety issues since serious side effects possibly occurred by administration of long period treatment.

Keyword

참고문헌 (42)

World Health Organization. Global Tuberculosis Report 2022 (ISBN 978-92-4-006173-6) Available from https://www.who.int/publications/i/item/9789240061729 Accessed December 20, 2023.？
Surendra K, Mohan A. Multidrug-resistant tuberculosis:a menace that threatens to destabilize tuberculosis control. Chest 2006;130(1):261-72.？

상세보기
Yang JS, Kim KJ, Choi H, et al. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance related gene mutations in multidrug-resistant and extensively drug-resistant. tuberculosis in Korea. Ann. Lab. Med. 2018;38(6):563-8.？

상세보기
Zong Z, Jing W, Shi J, et al. Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis in China. Antimicrob Agents Chemother 2018;62(8):e00165-18.？

상세보기
Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort. Clin. Infect. Dis. 2015;60(2):188-94.？

상세보기
Rey-Jurado E, Tudo G, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int. J. Antimicrob. Agents 2013;41(3):278-80.？

상세보기
Eker B, Ortmann J, Migliori GB, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg. Infect. Dis. 2008;14(11):1700-6.？

상세보기
World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease Available from https://www.who.int/publications/i/item/9789240022676 Accessed December 20, 2023.？
Alcala L, Ruiz-Serrano MJ, Turegano CP, et al. In vitro activities of linezolid against clinical isolates of mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47(1):416-7.？

상세보기
Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2008;178(11):1180-5.？

상세보기
Strydom N, Gupta SV, Fox WS, et al. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16(4):e1002773.？

상세보기
Tsona A, Metallidis S, Foroglou N, et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J. Chemother. 2010;22(1):17-9.？

상세보기
Thirot H, Briquet C, Frippiat F, et al. Clinical use and adverse drug reaction of linezolid: a retrospective study in four Belgian hospital centers, Antibiotics (Basel). 2021;10(5):530.？

상세보기
Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2010;65(4):775-83.？

상세보기
Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134(1):187-92.？

상세보기
Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2005;56(1):180-5.？

상세보기
Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of dailyhalf dose linezolid in patients with intractable multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2006;58(3):701-4.？

상세보기
Lee CM. The short-term therapeutic effect of Linezolid in the patients with multi-drug resistant pulmonary tuberculosis. Mokpo National Hospital 2012:40-59.？
Roongruangpitayakul C, Chuchottaworn C. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand. In J Med Assoc Thai 2013;96(10):1273-82.？

상세보기
Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases 2010;50(1):49-55.？

상세보기
Liu Y, Bao P, Wang D, et al. Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Japanese Journal of Infectious Diseases 2015;68(3):244-7.？

상세보기
Lifan Z, Sainan B, Feng S, et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease 2019;23(12):1293-307.？

상세보기
Lorenzo SD, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. In European Respiratory Journal 2012;39:770-72.？

상세보기
Dayyab F, Iliyasu G, Ahmad B, et al. Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-western Nigeria. International Journal of Mycobacteriology 2021;10(2):129-35.？
Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2016;15(1):1-17.？

상세보기
O'Meara P, Guenette JA, Raghavan N, et al. Mechanisms of dyspnea relief following radiation treatment in a patient with severe COPD. In European Respiratory Journal 2011;38:728-30.？

상세보기
Xu HB, Jiang RH, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. International Journal of Tuberculosis and Lung Disease 2012; 16(3):358-63.？

상세보기
Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. Journal of Antimicrobial Chemotherapy 2012;67(2):473-7.？

상세보기
Yi L, Yoshiyama T, Okumura M, et al. Linezolid as a potentially effective drug for the treatment of multidrug-resistant tuberculosis in Japan. Japanese Journal of Infectious Diseases 2017;70(1):96-9.？

상세보기
Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2009;64(2):388-91.？

상세보기
Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal 2008;34(2):387-93.？

상세보기
Nam HS, Koh WJ, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. In International Journal of Antimicrobial Agents 2009;33(1):92-3.？

상세보기
von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis - a report of ten cases. Journal of Infection 2006;52(2):92-6.？

상세보기
Zhang L, Pang Y, Yu X, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection 2014;42(4):705-11.？

상세보기
Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. In European Respiratory Journal 2014;45(1):161-70.？

상세보기
Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New England Journal of Medicine 2012;367(16):1508-18.？

상세보기
Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. European Respiratory Journal 2012;39(4):956-62.？

상세보기
Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. In European Respiratory Journal 2011;38:730-3.？

상세보기
Tang S, Zhang Q, Yu J, et al. Extensively drug-resistant tuberculosis, China. In Emerging Infectious Diseases 2011;17(3):558-60.？

상세보기
Tse-Chang A, Kunimoto D, Der E, et al. Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: a retrospective case review. Can J Infect Dis Med Microbiol. 2013;24(3):e50-2.？
Koh WJ, Kwon OJ, Gwak HS et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2009;64:388-91.？

상세보기
Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR and XDR-TB: an Indian perspective. Eur Respir J. 2010;35(4):936-8.

상세보기

저자의 다른 논문 :

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증